# US 2026/0216057 A1 · Pharmaceutical compositions for herpes virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216057 A1
- Document ID: US20260216057A1
- Status: Published application
- Kind: A1
- Application number: 19/106,392
- Filed: 2023-08-28
- Published: 2026-07-30
- Earliest claimed: 2022-08-29
- Assignees: Assembly Biosciences, Inc.
- Applicants: Assembly Biosciences, Inc.
- Inventors: Zhixin ZONG; Nicole WHITE; Yi WU
- Web page: https://patentgrep.com/patent/US20260216057A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods and compositions for treating and/or inhibiting the development or progression of diseases or disorders caused by, or associated with, herpes virus infection. In particular, provided are long-acting injectable depot pharmaceutical compositions comprising a helicase-primase inhibitor; methods for their manufacture; and the use of said pharmaceutical compositions as a medicament and for the treatment of diseases or disorders caused by, or associated with, herpes virus.

## Claims

### Claim 1

A long-acting injectable depot pharmaceutical composition comprising:
(a) a helicase-primase inhibitor or a pharmaceutically acceptable salt thereof; and
(b) one or more pharmaceutically acceptable excipients;
wherein the helicase-primase inhibitor has a human biological terminal half-life of 10 hours or more.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the composition is a subcutaneous or intramuscular long-acting injectable depot pharmaceutical composition.

### Claim 3 (depends on 2)

The composition according to claim 2, wherein the composition is for administration twice a month, once a month, once every two months, once every three months, once every six months or once every year.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the helicase-primase inhibitor has an in-vitro EC50 value of less than 0.1 μM against HSV-1 and/or HSV-2.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the helicase-primase inhibitor is N-Methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phenyl]acetamide:
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the helicase-primase inhibitor is N-Methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phenyl]acetamide free base.

### Claim 7 (depends on 6)

The composition according to claim 6, wherein the free base is present as a crystalline solid.

### Claim 8 (depends on 6)

The composition according to claim 6, wherein the long-acting injectable depot pharmaceutical composition is an aqueous suspension and the free base is suspended as a crystalline solid.

### Claim 9 (depends on 8)

The composition according to claim 8, wherein the long-acting injectable depot pharmaceutical composition is an aqueous nanosuspension and the free base is suspended as a crystalline solid.

### Claim 10 (depends on 1)

The composition according to claim 1, wherein the long-acting injectable depot pharmaceutical composition comprises a solution in organic solvent based formulation.

### Claim 11 (depends on 10)

The composition according to claim 10, wherein the organic solvent is selected from benzyl alcohol, benzyl benzoate, N-methyl-pyrrolidone (NMP), 2-pyrrolidone, ethanol, propylene glycol, acetone, methyl acetate, ethyl acetate, methyl ethyl ketone, dimethylacetamide (DMA), dimethylformamide, dimethyl sulfoxide (DMSO), tetrahydrofuran, caprolactam, oleic acid, 1-dodecylazacycloheptan-2-one, and mixture thereof.

### Claim 12 (depends on 10)

The composition according to claim 10, wherein the helicase-primase inhibitor is N-Methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phenyl]-acetamide and the organic solvent is selected from NMP, DMA and DMSO.

### Claim 13 (depends on 1)

The composition according to claim 1, wherein the helicase-primase inhibitor is 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methyl-thiazole-5-sulfonamide (Compound 1):
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The composition according to claim 1, wherein the helicase-primase inhibitor is 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide free form.

### Claim 15 (depends on 14)

The composition according to claim 14, wherein the free form is present as a crystalline solid.

### Claim 16 (depends on 14)

The composition according to claim 14, wherein the long-acting injectable depot pharmaceutical composition is an aqueous suspension and the free form is suspended as a crystalline solid.

### Claim 17 (depends on 16)

The composition according to claim 16, wherein the long-acting injectable depot pharmaceutical composition is an aqueous microsuspension or nanosuspension and the free form is suspended as a crystalline solid.

### Claim 18 (depends on 13)

The composition according to claim 13, wherein the long-acting injectable depot pharmaceutical composition comprises a solution in organic solvent based formulation.

### Claim 19 (depends on 18)

The composition according to claim 18, wherein the organic solvent is selected from N-methyl pyrrolidone (NMP), dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), benzyl alcohol, benzyl benzoate and mixtures thereof.

### Claim 20 (depends on 19)

The composition according to claim 19, wherein the organic solvent is selected from NMP, DMA and DMSO.

### Claim 21 (depends on 1)

The composition according to claim 1, wherein the long-acting injectable depot pharmaceutical composition comprises about 2 wt % to about 40 wt % of a helicase-primase inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 1)

The composition according to claim 1, wherein the long-acting injectable depot pharmaceutical composition comprises about 100 mg to about 1200 mg, about 10 mg to about 900 mg or about 100 mg to about 600 mg of a helicase-primase inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

The composition according to claim 1, wherein the long-acting injectable depot pharmaceutical composition comprises N-Methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phenyl]acetamide free base as the helicase-primase inhibitor and the composition produces a plasma concentration of N-Methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phenyl]acetamide in the subject after administration of at least 25 ng/mL for at least 80% of the dosing interval, wherein the dosing interval is at least 10 days.

### Claim 24 (depends on 1)

The composition according to claim 1, wherein the long-acting injectable depot pharmaceutical composition comprises 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1 (2H)-yl)-4-methylthiazole-5-sulfonamide free form as the helicase-primase inhibitor and the composition produces a plasma concentration of 2-(3-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide in the subject after administration of at least 25 ng/mL for at least 80% of the dosing interval, wherein the dosing interval is at least 10 days.

### Claim 25 (depends on 1)

The composition according to claim 1, wherein the composition is stable for at least four weeks.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

A method for treating a herpes virus (such as HSV) infection in a subject in need thereof, the method comprising administering a therapeutically effective amount of a helicase-primase inhibitor, or a pharmaceutically acceptable salt thereof, to the subject wherein the helicase-primase inhibitor or a pharmaceutically acceptable salt thereof, is formulated as a pharmaceutical composition according to claim 1.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the pharmaceutical composition is administered twice a month, once a month, once every two months, once every three months, once every six months, or once every year.

### Claim 29 (depends on 27)

The method according to claim 27, wherein the pharmaceutical composition is administered once a month, or once every three months.
